Vasoactive intestinal polypeptide
- Rodger A Liddle, MD
Rodger A Liddle, MD
- Professor of Medicine
- Duke University Medical School
Vasoactive intestinal polypeptide (VIP) is a neuropeptide that functions as a neuromodulator and neurotransmitter. It is a potent vasodilator, regulates smooth muscle activity, epithelial cell secretion, and blood flow in the gastrointestinal tract [1-3]. As a chemical messenger, it functions as a neurohormone and paracrine mediator, being released from nerve terminals and acting locally on receptor-bearing cells.
The VIP receptor is a member of a unique class of G protein-coupled receptors. These receptors share a significant degree of sequence homology (>50 percent), which distinguishes them from members of the rhodopsin/beta-adrenergic family (class I) . (See "Peptide hormone signal transduction and regulation".)
Like other gastrointestinal peptides, vasoactive intestinal polypeptide (VIP) is synthesized as a precursor molecule with a signal peptide containing 22 amino acids, which is then cleaved to the active peptide of 28 amino acids [5,6]. The gene encoding this peptide resides on chromosome 6 . Some studies have demonstrated local control of VIP gene expression as VIP mRNA does not always parallel the peptide product . These data suggest regulation at the post-transcriptional stage may be essential for normal VIP secretion .
The VIP peptide is remarkably well conserved across species and is identical in human, cow, pig, rat, dog, and goat species . Even across species, amino acid substitutions are conservative and usually do not result in changes in bioactivity.
Alternative peptides derived from the VIP gene include peptide histidine isoleucine (PHI) , peptide histidine methionine [10,11], and peptide histidine valine . Although the functional significance of these peptides is unclear, PHI is known to stimulate intestinal fluid secretion .
- Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970; 169:1217.
- Said SI, Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature 1970; 225:863.
- Dockray GJ. Vasoactive intestinal polypeptide and related peptides. In: Gut Hormones: Biochemistry and Physiology, 1st ed, Walsh JH, Dockray GJ (Eds), Raven Press, New York 1994. p.447.
- Birnbaumer M. Mutations and diseases of G protein coupled receptors. J Recept Signal Transduct Res 1995; 15:131.
- Linder S, Barkhem T, Norberg A, et al. Structure and expression of the gene encoding the vasoactive intestinal peptide precursor. Proc Natl Acad Sci U S A 1987; 84:605.
- Maggi CA, Giachetti A, Dey RD, Said SI. Neuropeptides as regulators of airway function: vasoactive intestinal peptide and the tachykinins. Physiol Rev 1995; 75:277.
- Gozes I, Nakai H, Byers M, et al. Sequential expression in the nervous system of c-myb and VIP genes, located in human chromosomal region 6q24. Somat Cell Mol Genet 1987; 13:305.
- Gozes I, Shani Y, Rostène WH. Developmental expression of the VIP-gene in brain and intestine. Brain Res 1987; 388:137.
- Christofides ND, Yiangou Y, Blank MA, et al. Are peptide histidine isoleucine and vasoactive intestinal peptide co-synthesised in the same pro-hormone? Lancet 1982; 2:1398.
- Bodner M, Fridkin M, Gozes I. Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome. Proc Natl Acad Sci U S A 1985; 82:3548.
- Yiangou Y, Williams SJ, Bishop AE, et al. Peptide histidine-methionine immunoreactivity in plasma and tissue from patients with vasoactive intestinal peptide-secreting tumors and watery diarrhea syndrome. J Clin Endocrinol Metab 1987; 64:131.
- Ghiglione M, Christofides ND, Yiangou Y, et al. PHI stimulates intestinal fluid secretion. Neuropeptides 1982; 3:79.
- Ekblad E, Winther C, Ekman R, et al. Projections of peptide-containing neurons in rat small intestine. Neuroscience 1987; 20:169.
- Porter AJ, Wattchow DA, Brookes SJ, Costa M. Projections of nitric oxide synthase and vasoactive intestinal polypeptide-reactive submucosal neurons in the human colon. J Gastroenterol Hepatol 1999; 14:1180.
- Adeghate E. Distribution of calcitonin-gene-related peptide, neuropeptide-Y, vasoactive intestinal polypeptide, cholecystokinin-8, substance P and islet peptides in the pancreas of normal and diabetic rats. Neuropeptides 1999; 33:227.
- Kitanishi T, Suzuki M, Kitano H, et al. Immunohistochemical detection of vasoactive intestinal polypeptide (VIP) and the VIP receptor in the rat inner ear. Acta Otolaryngol Suppl 1998; 539:52.
- Houdeau E, Prudhomme MJ, Rousseau JP. Regional difference in the distribution of vasoactive intestinal polypeptide-immunoreactive nerve fibres along the uterus and between myometrial muscle layers in the rat. Histochem J 1998; 30:525.
- Alexandre D, Anouar Y, Jegou S, et al. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals. Endocrinology 1999; 140:1285.
- Vertongen P, Schiffmann SN, Gourlet P, Robberecht P. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Ann N Y Acad Sci 1998; 865:412.
- Harmar AJ, Arimura A, Gozes I, et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998; 50:265.
- Fahrenkrug J. Transmitter role of vasoactive intestinal peptide. Pharmacol Toxicol 1993; 72:354.
- Bitar KN, Said SI, Weir GC, et al. Neural release of vasoactive intestinal peptide from the gut. Gastroenterology 1980; 79:1288.
- Verner JV, Morrison AB. Endocrine pancreatic islet disease with diarrhea. Report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases. Arch Intern Med 1974; 133:492.
- Bloom SR. Vasoactive intestinal peptide, the major mediator of the WDHA (pancreatic cholera) syndrome: value of measurement in diagnosis and treatment. Am J Dig Dis 1978; 23:373.
- Masel SL, Brennan BA, Turner JH, et al. Pancreatic vasoactive intestinal polypeptide-oma as a cause of secretory diarrhoea. J Gastroenterol Hepatol 2000; 15:457.
- Lundberg JM, Fahrenkrug J, Larsson O, Anggård A. Corelease of vasoactive intestinal polypeptide and peptide histidine isoleucine in relation to atropine-resistant vasodilation in cat submandibular salivary gland. Neurosci Lett 1984; 52:37.
- Holst JJ, Fahrenkrug J, Knuhtsen S, et al. VIP and PHI in the pig pancreas: coexistence, corelease, and cooperative effects. Am J Physiol 1987; 252:G182.
- Yasui A, Naruse S, Yanaihara C, et al. Corelease of PHI and VIP by vagal stimulation in the dog. Am J Physiol 1987; 253:G13.
- Li CG, Rand MJ. Nitric oxide and vasoactive intestinal polypeptide mediate non-adrenergic, non-cholinergic inhibitory transmission to smooth muscle of the rat gastric fundus. Eur J Pharmacol 1990; 191:303.
- Van Geldre LA, Lefebvre RA. Interaction of NO and VIP in gastrointestinal smooth muscle relaxation. Curr Pharm Des 2004; 10:2483.
- Fahrenkrug J, Hannibal J. Neurotransmitters co-existing with VIP or PACAP. Peptides 2004; 25:393.
- Barada KA, Saadé NE, Atweh SF, Nassar CF. Neural mediation of vasoactive intestinal polypeptide inhibitory effect on jejunal alanine absorption. Am J Physiol 1998; 275:G822.
- Cho WK, Boyer JL. Vasoactive intestinal polypeptide is a potent regulator of bile secretion from rat cholangiocytes. Gastroenterology 1999; 117:420.
- Rattan S, Fan YP, Chakder S. Mechanism of inhibition of VIP-induced LES relaxation by heme oxygenase inhibitor zinc protoporphyrin IX. Am J Physiol 1999; 276:G138.
- Motomura Y, Chijiiwa Y, Yasuda O, et al. Thyrotropin-releasing hormone interacts with vasoactive intestinal peptide-specific receptor in guinea pig cecal circular smooth muscle cells. Regul Pept 2000; 87:41.
- Jiang S, Kopras E, McMichael M, et al. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. Cancer Res 1997; 57:1475.
- Goyal RK, Rattan S, Said SI. VIP as a possible neurotransmitter of non-cholinergic non-adrenergic inhibitory neurones. Nature 1980; 288:378.
- Grider JR. Interplay of VIP and nitric oxide in regulation of the descending relaxation phase of peristalsis. Am J Physiol 1993; 264:G334.
- Sababi M, Hällgren A, Nylander O. Interaction between prostanoids, NO, and VIP in modulation of duodenal alkaline secretion and motility. Am J Physiol 1996; 271:G582.
- Pozo D, Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J 2004; 18:1325.
- Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004; 56:249.
- Ganea D, Hooper KM, Kong W. The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiol (Oxf) 2015; 213:442.
- Pozo D, Gonzalez-Rey E, Chorny A, et al. Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. Peptides 2007; 28:1833.
- Deng S, Xi Y, Wang H, et al. Regulatory effect of vasoactive intestinal peptide on the balance of Treg and Th17 in collagen-induced arthritis. Cell Immunol 2010; 265:105.
- Arranz A, Abad C, Juarranz Y, et al. Vasoactive intestinal peptide as a healing mediator in Crohn's disease. Neuroimmunomodulation 2008; 15:46.
- Jönsson M, Norrgård O, Hansson M, Forsgren S. Decrease in binding for the neuropeptide VIP in response to marked inflammation of the mucosa in ulcerative colitis. Ann N Y Acad Sci 2007; 1107:280.
- Neunlist M, Toumi F, Oreschkova T, et al. Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways. Am J Physiol Gastrointest Liver Physiol 2003; 285:G1028.
- Margolis KG, Gershon MD. Neuropeptides and inflammatory bowel disease. Curr Opin Gastroenterol 2009; 25:503.
- Hamasaki Y, Mojarad M, Said SI. Relaxant action of VIP on cat pulmonary artery: comparison with acetylcholine, isoproterenol, and PGE1. J Appl Physiol Respir Environ Exerc Physiol 1983; 54:1607.
- Hamidi SA, Prabhakar S, Said SI. Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur Respir J 2008; 31:135.
- Dewachter L, Dewachter C, Naeije R. New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation. Expert Opin Investig Drugs 2010; 19:469.
- Cernuda-Morollón E, Martínez-Camblor P, Ramón C, et al. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache 2014; 54:987.
- Tajti J, Szok D, Majláth Z, et al. Migraine and neuropeptides. Neuropeptides 2015; 52:19.
- Moody TW, Moreno P, Jensen RT. Neuropeptides as lung cancer growth factors. Peptides 2015; 72:106.
- Said SI, Faloona GR. Elevated plasma and tissue levels of vasoactive intestinal polypeptide in the watery-diarrhea syndrome due to pancreatic, bronchogenic and other tumors. N Engl J Med 1975; 293:155.
- Smith SL, Branton SA, Avino AJ, et al. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 1998; 124:1050.
- Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994; 331:1116.
- Pallela VR, Thakur ML, Chakder S, Rattan S. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med 1999; 40:352.
- Palsson OS, Morteau O, Bozymski EM, et al. Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. Dig Dis Sci 2004; 49:1236.
- Larsson LT, Sundler F. Is the reduction of VIP the clue to the pathophysiology of Hirschsprung's disease? Z Kinderchir 1990; 45:164.
- Aggestrup S, Uddman R, Sundler F, et al. Lack of vasoactive intestinal polypeptide nerves in esophageal achalasia. Gastroenterology 1983; 84:924.
- Heinz-Erian P, Dey RD, Flux M, Said SI. Deficient vasoactive intestinal peptide innervation in the sweat glands of cystic fibrosis patients. Science 1985; 229:1407.
- Vaidya B, Gupta V. Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery. J Control Release 2015; 211:118.
- Gonzalez-Rey E, Varela N, Chorny A, Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr Pharm Des 2007; 13:1113.